Современные представления о терапии увеитов при иммуновоспалительных ревматических заболеваниях

Неинфекционный увеит является ведущей и недостаточно изученной причиной необратимого снижения зрения у больных иммуновоспалительными ревматическими заболеваниями (ИВРЗ). Статья посвящена актуальным клиническим и терапевтическим вопросам, связанным с неинфекционным увеитом у больных ИВРЗ с акцентом на современные подходы к терапии. 

1. Неинфекционные увеиты. Клинические рекомендации ООО «Ассоциация врачей-офтальмологов», ООО «Общество офтальмологов России», 2019 г. http://avo-portal.ru/doc/fkr/development/item/343-neinfektsionnye-uveity; https://oor.ru/vracham/klrek/proekt-klinicheskikh-rekomendatsiyneinfektsionnye-uveity-dlya-obsuzhdeniya/

2. Rosenbaum JT, Bodaghi B, Couto C, Zierhut M, Acharya N, Pavesio C, Tay-Kearney ML, Neri P, Douglas K, Pathai S, Song AP, Kron M, Foster CS. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum 2019; 49(3): 438-445 doi: 10.1016/j.semarthrit.2019.06.004

3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardiza-tion of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057

4. Deschenes J, Murray P, Rao N, Nussenblatt R. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis. Ocular Immunology and Inflammation. 2008; 16(1-2): 1-2. doi:10.1080/09273940801899822

5. Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm. 2018; 26 (1): 2-16. doi:10.1080/09273948.2016.1196713

6. Chora I, Borges T, Dias C, Ourique C, Vilaça J, et al. Clinical Management of Uveitis in Systemic Rheumatic Autoimmune Diseases in Adults. Autoimmun Infec Dis. 2015; 1 (1): doi http://dx.doi.org/10.16966/2470-1025.104

7. Juanola X, Loza Santamaria E, Cordero-Coma M. Sentinel Working Group. Description and prevalence of spondyloarthritis in patients with anterior uveitis: the SENTINEL Interdisciplinary Collaborative Project. Ophthalmology. 2016; 123: 1632–6 https://doi.org/10.1016/j.ophtha.2016.03.010

8. Forrester JV, Kuffova L, Dick AD. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am J Ophthalmology. 2018;189:77-85. doi:10.1016/j.ajo.2018.02.019

9. Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2020;100866. doi:10.1016/j.preteyeres.2020.100866

10. Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018; 125 (5): 757–773. doi:10.1016/j.ophtha.2017.11.017

11. Valenzuela RA, Flores I, Urrutia B, et al. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview. Front Pharmacol. 2020;11:655. Published 2020 May 8. doi:10.3389/fphar.2020.00655

12. Choi J, Hawley DP, Ashworth J, Edelsten C, Bossuyt ASAM. An update on the modern management of paediatric uveitis. Br J Ophthalmol. 2019;103(12):1685-1689. doi:10.1136/bjophthalmol-2019-314212

13. Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019;19(5):477-490. doi:10.1080/14712598.2019.1595578

14. Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, Do DV, Nguyen QD. New therapies in development for the management of non-infectious uveitis: A review. Clin. Experiment. Ophthalmol. 2019; 47: 396–417. doi: 10.1111/ceo.13511

15. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008; 15 (1): 47-55 doi: 10.1080/09286580701585892

16. Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011; 16 (2): 309-322. doi: 10.1517/14728214.2011.537824.

17. Schultz C. Voclosporin as a treatment for noninfectious uveitis. Ophthalmol Eye Dis. 2013; 5: 5-10. doi: 10.4137/OED.S7995

18. Leal I, Rodrigues FB, Sousa DC, et al. Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and MetaAnalysis of Randomized Controlled Trials. Front Med (Lausanne). 2019;6:104. doi:10.3389/fmed.2019.00104

19. Ming S, Xie K, He H, Li Y, Lei B. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;12:2005-2016. doi:10.2147/DDDT.S160431

20. Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019;30(3):138-150. doi:10.1097/ICU.0000000000000562

21. Ahmed A, Foster CS. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis. Ophthalmic Res. 2019;61(1):44-50. doi:10.1159/000486791

22. Urruticoechea-Arana A, Cobo-Ibáñez T, Villaverde-García V, et al. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review. Rheumatol Int. 2019;39(1):47-58. doi:10.1007/s00296-018-4193-z

23. Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17. doi:10.1186/s12348- 019-0182-y

24. Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. Am J Ophthalmol. 2017;183:71-80. doi:10.1016/j.ajo.2017.08.019

25. Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): The Phase 2 SATURN Study. Ophthalmology. 2019;126(3):428-437. doi:10.1016/j.ophtha.2018.09.044

26. Dick AD, Tugal-Tutkun l, Foster S, Zierhut M, Liew SHM, Bezlyak V, Androudi S. Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology. 2013; 120: 777-787 https://doi.org/10.1016/j.ophtha.2012.09.040

27. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73-84. doi:10.1016/S0140-6736(16)31591-4

28. Molto A, Sieper J. Peripheral spondyloarthritis: Concept, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2018;32(3):357-368. doi:10.1016/j.berh.2019.02.010

29. Rudwaleit M, Landewe R, van der Heijde D, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-83. doi: 10.1136/ard.2009.1082335

30. Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spon-dyloarthritis in general. Ann Rheum Dis. 201; 70 (1): 25-31. doi: 10.1136/ard.2010.133645

31. Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):802- 825. doi:10.1016/j.berh.2016.10.007

32. Годзенко АА, Бочкова АГ, Румянцева ОА и др. Течение и исходы увеита у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2014;52(5):520–525. doi: 10.14412/1995-4484-2014-520-525.

33. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846-862. doi:10.1016/j.berh.2018.08.002

34. Mitulescu TC, Trandafir M, Dimăncescu MG, et al. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy? Rom J Ophthalmol. 2018;62(2):114-122

35. Mugheddu C, Atzori L, Del Piano M, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5): e12527. doi: 10.1111/dth.12527

36. Бекетова ТВ. Системные васкулиты. Российские клинические рекомендации. Ревматология. под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017. С.180–205.

37. Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):3- 20. doi:10.1016/j.berh.2018.10.003

38. Tugal-Tutkun I. Systemic vasculitis and the eye. Curr Opin Rheumatol. 2017;29(1):24-32. doi:10.1097/BOR.0000000000000345

39. Лисицына ТА, Алекберова ЗС, Голоева РГ, Давыдова ГА. Болезнь Бехчета: клинические проявления, современные принципы диагностики и терапии. Научно-практическая ревматология. 2019; 57(5): 553-563. doi: 10.14412/1995-4484-2019-553-563

40. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behçet syndrome: a contemporary view [published correction appears in Nat Rev Rheumatol. 2018 Jan 24;14 (2):119]. Nat Rev Rheumatol. 2018;14(2):107-119. doi:10.1038/nrrheum.2017.208

41. Ksiaa I, Abroug N, Kechida M, et al. Eye and Behçet’s disease. J Fr Ophtalmol. 2019;42(4):e133-e146. doi:10.1016/j.jfo.2019.02.002

42. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225

43. Лисицына ТА, Алекберова ЗС, Голоева РГ. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019; 57(2):133-141. doi: 10.14412/1995-4484-2019-133-141

44. Uke P, Gorodkin R, Beare N. Biologic therapy for Behçet’s uveitis: a systematic review. Br J Ophthalmol. 2020;104(8):1045-1051. doi:10.1136/bjophthalmol-2019-314154

45. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. Ann Intern Med. 2008; 149 (4):284-286. doi: 10.7326/0003-4819-149-4-200808190-00018

46. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juve-nile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis. 2012; 71(9): 1589-1591. doi: 10.1136/annrheumdis-2012-201383

47. Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet’s disease. Clin Exp Rheumatol. 2017; 35 (6 suppl 108):130-131

48. Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018; 25:1-11. doi: 10.1080/09273948.2017.1421233

49. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi: 10.1016/S0140-6736(16)30173-8

50. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-2149. doi:10.1016/S0140-6736(11)60244-4

51. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322. doi:10.1016/j.clim.2019.108322

52. Ferrara G, Mastrangelo G, Barone P, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. doi:10.1186/s12969-018-0255-8

53. Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107-1117. doi:10.1136/annrheumdis-2018-213131

54. Катаргина ЛА, Бржеский ВВ, Гусева МР, Денисова ЕВ, Дроздова ЕА, Жукова ОВ, Никишина ИП, Старикова АВ. Федеральные клинические рекомендации «Диагностика и лечение увеитов, ассоциированных с ювенильным идиопатическим артритом». Российская педиатрическая офтальмология. 2016; 11 (2): 102-111. doi: 10.18821/1993-1859-2016-11-2-102-111

55. Heiligenhaus A, Minden K, Tappeiner C, Baus H, Bertram B, Deuter C, et al. Update of the evidence based, interdisciplinary guideline for antiinflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism. 2019; 49: 43-55. https://doi.org/10.1016/j.semarthrit.2018.11.004

56. Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: новые горизонты диагностики и терапии. Научнопрактическая ревматология. 2020; 58(1): 5-14. doi:10.14412/1995-4484-2020-5-14

57. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi:10.1016/S0140-6736(19)30546-X

58. Cunningham ET, Tabbara KF, Zierhut M. Systemic Lupus Erythematosus and the Eye. Ocul Immunol Inflamm. 2018;26(8):1143-1145. doi:10.1080/09273948.2018.1539589

59. Krainer J, Siebenhandl S, Weinhäusel A. Systemic autoinflammatory diseases. J Autoimmun. 2020;109:102421. doi:10.1016/j. jaut.2020.102421

60. Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V. Systemic autoinflammatory diseases: Clinical state of the art. Best Pract Res Clin Rheumatol. 2020;101529. doi:10.1016/j.berh.2020.101529

61. Салугина СО, Кузьмина НН, Федоров ЕС. Аутовоспалительные синдромы – «новая» мультидисциплинарная проблема педиатрии и ревматологии. Педиатрия 2012; 91 (5): 120-132.

62. Hausmann JS. Targeting cytokines to treat autoinflammatory diseases. Clin Immunol. 2019;206:23-32. doi:10.1016/j.clim.2018.10.016